Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK and Safety Study of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
2024-512651-20-00Phase 2Completed
- Sponsor
- Rallybio
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of RLYB212 in fetomaternal alloimmune thrombocytopenia (FMAIT), sponsored by Rallybio. Primary endpoints: Maternal pharmacokinetic parameters of RLYB212 and Maternal safety of RLYB212. Started Oct 2024; status: completed.
02
Drugs
RLYB212
03
Conditions
fetomaternal alloimmune thrombocytopenia (FMAIT)
Beyond the preview
Go deeper on 2024-512651-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512651-20-00.